Skip to main content

Carotid Artery Disease

3
Pipeline Programs
8
Companies
15
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 14 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
6 programs
1
Carotid artery stenting with filterPhase 41 trial
Carotid artery stenting with filterN/A1 trial
RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6N/A1 trial
RX ACCULINK, RX ACCUNET Embolic Protection SystemN/A1 trial
RX Acculink Carotid Stent SystemN/A1 trial
+1 more programs
Active Trials
NCT00106938Terminated1,663Est. Mar 2013
NCT00406055Completed18,855Est. Jun 2012
NCT00302237Completed6,426Est. May 2010
+3 more trials
Boston Scientific
Boston ScientificCA - Valencia
2 programs
1
Carotid WALLSTENT Monorail EndoprosthesisPhase 41 trial
Carotid Artery StentingN/A1 trial
Active Trials
NCT01133327Completed100Est. Jun 2012
NCT00741091Completed1,097Est. Oct 2010
Medtronic
MedtronicNJ - Phillipsburg
3 programs
1
PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection DevicePhase 31 trial
Mo.Ma cerebral protection deviceN/A1 trial
PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection DeviceN/A1 trial
Active Trials
NCT00744523Completed262Est. Mar 2009
NCT00530504Completed1,500Est. Jan 2014
NCT00619775Completed419Est. Oct 2005
Cordis
CordisFL - Miami Lakes
2 programs
-PRECISE Nitinol Stent SystemPHASE_31 trial
Cordis Nitinol StentPHASE_31 trial
Active Trials
NCT00231231Completed1,500Est. Nov 2006
NCT00231270Completed1,300Est. Aug 2005
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
simvastatinN/ASmall Molecule
MSD
MSDIreland - Ballydine
1 program
simvastatinN/ASmall Molecule1 trial
Active Trials
NCT00587717Completed35Est. Mar 2006
GE HealthCare
1 program
OptisonPHASE_21 trial
Active Trials
NCT01394926Terminated21Est. Jun 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boston ScientificCarotid WALLSTENT Monorail Endoprosthesis
AbbottCarotid artery stenting with filter
Cordis-PRECISE Nitinol Stent System
MedtronicPROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device
CordisCordis Nitinol Stent
GE HealthCareOptison
AbbottRX Acculink Carotid Stent System
Boston ScientificCarotid Artery Stenting
MedtronicMo.Ma cerebral protection device
MedtronicPROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device
AbbottXact Stent with either Emboshield Pro
AbbottRX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
AbbottRX ACCULINK, RX ACCUNET Embolic Protection System
AbbottCarotid artery stenting with filter
MSDsimvastatin

Clinical Trials (15)

Total enrollment: 36,203 patients across 15 trials

NCT00741091Boston ScientificCarotid WALLSTENT Monorail Endoprosthesis

A Carotid Stenting Boston Scientific Surveillance Program

Start: Dec 2008Est. completion: Oct 20101,097 patients
Phase 4Completed
NCT00287508AbbottCarotid artery stenting with filter

Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)

Start: Nov 2005Est. completion: Jan 20081,500 patients
Phase 4Completed
NCT00231231Cordis-PRECISE Nitinol Stent System

Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)

Start: Sep 2004Est. completion: Nov 20061,500 patients
Phase 3Completed
NCT00619775MedtronicPROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device

Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial

Start: Apr 2004Est. completion: Oct 2005419 patients
Phase 3Completed
NCT00231270CordisCordis Nitinol Stent

Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)

Start: Aug 2000Est. completion: Aug 20051,300 patients
Phase 3Completed
NCT01394926GE HealthCareOptison

Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease

Start: Jun 2011Est. completion: Jun 201221 patients
Phase 2Terminated
NCT01445613AbbottRX Acculink Carotid Stent System

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

Start: Oct 2011Est. completion: Mar 20161,203 patients
N/ACompleted
NCT01133327Boston ScientificCarotid Artery Stenting

Adapt Monorail Carotid Stent System: A Postmarket Clinical Follow-up Study

Start: Jun 2010Est. completion: Jun 2012100 patients
N/ACompleted
NCT00744523MedtronicMo.Ma cerebral protection device

Proximal Protection With The Mo.Ma Device During Carotid Stenting

Start: Sep 2007Est. completion: Mar 2009262 patients
N/ACompleted
NCT00530504MedtronicPROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device

Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study

Start: May 2007Est. completion: Jan 20141,500 patients
N/ACompleted
NCT00402740AbbottXact Stent with either Emboshield Pro

Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)

Start: Nov 2006Est. completion: Oct 2011322 patients
N/ACompleted
NCT00406055AbbottRX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6

CHOICE: Carotid Stenting For High Surgical-Risk Patients

Start: Oct 2006Est. completion: Jun 201218,855 patients
N/ACompleted
NCT00302237AbbottRX ACCULINK, RX ACCUNET Embolic Protection System

CAPTURE 2 Post-Marketing Registry

Start: Mar 2006Est. completion: May 20106,426 patients
N/ACompleted
NCT00106938AbbottCarotid artery stenting with filter

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

Start: Apr 2005Est. completion: Mar 20131,663 patients
N/ATerminated
NCT00587717MSDsimvastatin

The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue

Start: Sep 2002Est. completion: Mar 200635 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.